The DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.
Clinical, Pathological, and Molecular Variables Predictive of Malignant Peripheral Nerve Sheath Tumor Outcome
Abstract
In Brief Objective: Improved staging systems for malignant peripheral nerve sheath tumor (MPNST) prognostication and management are needed. Consequently, we sought to identify clinical, pathologic, and molecular predictors of outcome in patients with/without neurofibromatosis type 1 (NF-1) associated MPNST. Methods: MPNST patients treated from 1986 to 2006 (n = 140) were identified; 72 had NF-1 syndrome and 68 did not. A comprehensive database was constructed. Paraffin-embedded neurofibroma or MPNST blocks were assembled in a tissue microarray; marker expression was evaluated immunohistochemically. Univariable and multivariable analyses identified independent factors prognostic of local recurrence, distant metastasis, and disease-specific survival (DSS). Results: DSS at 10 years was 31.6% for 87 primary disease patients, 25.9% for 26 recurrent patients, and 7.5% for 27 metastatic patients after median follow up of 91 months. The 5 years DSS for localized tumor patients was 35% for NF-1 patients and 50% for sporadic patients. MPNST ≥10 cm at diagnosis, partial resection, and metastasis development were significant negative predictors of DSS; completely resected tumors that lacked S-100 immunoreactivity had a nearly 5-fold increased risk of developing distant metastasis. Ki67, vascular endothelial growth factor, p53, and pMEK were over-expressed in MPNST compared with benign neurofibromas. Only tumor size and nuclear p53 expression were found to be independent prognosticators for MPNST DSS in a multivariable analysis. Conclusions: MPSNT is a markedly metastatic and aggressive poor prognosis tumor. Multiple clinical, pathologic, and molecular markers identified in this study, coupled with findings from previous series, should be considered for an improved MPNST staging system useful for prognostic assessment and management decisions. Clinical, pathologic, and molecular predictors of outcome in patients with/without neurofibromatosis type 1 (NF-1) associated MPNST (n = 140) treated at a single institution were evaluated. Size ≥10 cm, partial resection, metastasis development, decreased S-100 and increased epidermal growth factor receptor and nuclear p53 expression levels were associated with significantly worse disease-specific MPNST survival in a univariable analysis. Tumor size and p53 expression levels remained independent in a multivariable analysis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Gerdes, J., Lemke, H., Baisch, H., Wacker, H. H., Schwab, U., & Stein, H. (1984) · The Journal of Immunology · doi:10.4049/jimmunol.133.4.1710 · Cited by 4,173
Malignant peripheral nerve sheath tumors. A clinicopathologic study of 120 cases
Ducatman, B. S., Scheithauer, B. W., Piepgras, D. G., Reiman, H. M., & Ilstrup, D. M. (1986) · Cancer · doi:10.1002/1097-0142(19860515)57:10<2006::aid-cncr2820571022>3.0.co;2-6 · Cited by 1,581
Malignant peripheral nerve sheath tumours in neurofibromatosis 1
Evans, D. G. R., Baser, M. E., McGaughran, J., Sharif, S., Howard, E., & Moran, A. (2002) · Journal of Medical Genetics · doi:10.1136/jmg.39.5.311 · Cited by 1,282
Pisters, P. W., Leung, D. H., Woodruff, J., Shi, W., & Brennan, M. F. (1996) · Journal of Clinical Oncology · doi:10.1200/jco.1996.14.5.1679 · Cited by 1,220
Cormier, J. N., & Pollock, R. E. (2004) · CA: A Cancer Journal for Clinicians · doi:10.3322/canjclin.54.2.94 · Cited by 835
Self-citationCoindre, J.-M., Terrier, P., Guillou, L., Le Doussal, V., Collin, F., Ranch�re, D., Sastre, X., Vilain, M.-O., Bonichon, F., & N'Guyen Bui, B. (2001) · Cancer · doi:10.1002/1097-0142(20010515)91:10<1914::aid-cncr1214>3.0.co;2-3 · Cited by 740
The NF1 tumor suppressor critically regulates TSC2 and mTOR
Johannessen, C. M., Reczek, E. E., James, M. F., Brems, H., Legius, E., & Cichowski, K. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0503224102 · Cited by 601
DeClue, J. E., Papageorge, A. G., Fletcher, J. A., Diehl, S. R., Ratner, N., Vass, W. C., & Lowy, D. R. (1992) · Cell · doi:10.1016/0092-8674(92)90407-4 · Cited by 580
Huson, S. M., Compston, D. A., Clark, P., & Harper, P. S. (1989) · Journal of Medical Genetics · doi:10.1136/jmg.26.11.704 · Cited by 540
Malignant peripheral nerve sheath tumor: analysis of treatment outcome
Wong, W. W., Hirose, T., Scheithauer, B. W., Schild, S. E., & Gunderson, L. L. (1998) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/s0360-3016(98)00223-5 · Cited by 458
Anghileri, M., Miceli, R., Fiore, M., Mariani, L., Ferrari, A., Mussi, C., Lozza, L., Collini, P., Olmi, P., Casali, P. G., et al. (2006) · Cancer · doi:10.1002/cncr.22098 · Cited by 436
LoRusso, P. M., Adjei, A. A., Varterasian, M., Gadgeel, S., Reid, J., Mitchell, D. Y., Hanson, L., DeLuca, P., Bruzek, L., Piens, J., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.14.415 · Cited by 401
Friday, B. B., & Adjei, A. A. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-4790 · Cited by 374
Carli, M., Ferrari, A., Mattke, A., Zanetti, I., Casanova, M., Bisogno, G., Cecchetto, G., Alaggio, R., De Sio, L., Koscielniak, E., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.01.4886 · Cited by 371
Malignant peripheral nerve sheath tumors of the buttock and lower extremity. A study of 43 cases
Hruban, R. H., Shiu, M. H., Senie, R. T., & Woodruff, J. M. (1990) · Cancer · doi:10.1002/1097-0142(19900915)66:6<1253::aid-cncr2820660627>3.0.co;2-r · Cited by 366
Association between benign and malignant peripheral nerve sheath tumors in NF1
Tucker, T., Wolkenstein, P., Revuz, J., Zeller, J., & Friedman, J. M. (2005) · Neurology · doi:10.1212/01.wnl.0000168830.79997.13 · Cited by 311
Identification and characterization of the neurofibromatosis type 1 protein product.
DeClue, J. E., Cohen, B. D., & Lowy, D. R. (1991) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.88.22.9914 · Cited by 215
Prognostic significance of Ki-67 reactivity in soft tissue sarcomas
Ueda, T., Aozasa, K., Tsujimoto, M., Ohsawa, M., Uchida, A., Aoki, Y., Ono, K., & Matsumoto, K. (1989) · Cancer · doi:10.1002/1097-0142(19890415)63:8<1607::aid-cncr2820630827>3.0.co;2-1 · Cited by 202
DeClue, J. E., Heffelfinger, S., Benvenuto, G., Ling, B., Li, S., Rui, W., Vass, W. C., Viskochil, D., & Ratner, N. (2000) · Journal of Clinical Investigation · doi:10.1172/jci7610 · Cited by 172
Induction of Abnormal Proliferation by Nonmyelinating Schwann Cells Triggers Neurofibroma Formation
Zheng, H., Chang, L., Patel, N., Yang, J., Lowe, L., Burns, D. K., & Zhu, Y. (2008) · Cancer Cell · doi:10.1016/j.ccr.2008.01.002 · Cited by 170
The Loss of Nf1 Transiently Promotes Self-Renewal but Not Tumorigenesis by Neural Crest Stem Cells
Joseph, N. M., Mosher, J. T., Buchstaller, J., Snider, P., McKeever, P. E., Lim, M., Conway, S. J., Parada, L. F., Zhu, Y., & Morrison, S. J. (2008) · Cancer Cell · doi:10.1016/j.ccr.2008.01.003 · Cited by 167
Drobnjak, M., Latres, E., Pollack, D., Karpeh, M., Dudas, M., Woodruff, J. M., Brennan, M. F., & Cordon-Cardo, C. (1994) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/86.7.549 · Cited by 161
S‐100 proteins in the human peripheral nervous system
González‐Martínez, T., Pérez‐Piñera, P., Díaz‐Esnal, B., & Vega, J. A. (2003) · Microscopy Research and Technique · doi:10.1002/jemt.10304 · Cited by 157
Smith, T., Machen, S. K., Fisher, C., et al. (1999) · American Journal of Clinical Pathology · doi:10.1093/ajcp/112.5.641 · Cited by 139
Kindblom, L. G., Ahld�n, M., Meis‐Kindblom, J. M., & Stenman, G. (1995) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/bf00203733 · Cited by 133
Angelov, L., Salhia, B., Roncari, L., McMahon, G., & Guha, A. (1999) · PubMed · Cited by 105
Leroy, K., Dumas, V., Martin‐Garcia, N., Falzone, M.-C., Voisin, M. C., Wechsler, J., Revuz, J. E., Créange, A., Levy, E., Lantieri, L. A., et al. (2001) · PubMed · Cited by 105
Hagel, C., Zils, U., Peiper, M., Kluwe, L., Gotthard, S., Friedrich, R. E., Zurakowski, D., von Deimling, A., & Mautner, V. F. (2006) · Journal of Neuro-Oncology · doi:10.1007/s11060-006-9266-2 · Cited by 88
Watanabe, T., Oda, Y., Tamiya, S., Kinukawa, N., Masuda, K., & Tsuneyoshi, M. (2001) · Histopathology · doi:10.1046/j.1365-2559.2001.01176.x · Cited by 73
Mawrin, C., Kirches, E., Boltze, C., Dietzmann, K., Roessner, A., & Schneider‐Stock, R. (2001) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s00428-001-0550-4 · Cited by 73
Donovan, S., See, W. L., Bonifas, J. M., Stokoe, D., & Shannon, K. (2002) · Cancer Cell · doi:10.1016/s1535-6108(02)00214-3 · Cited by 62
Prognostic Significance of Activated AKT Expression in Soft-Tissue Sarcoma
Tomita, Y., Morooka, T., Hoshida, Y., Zhang, B., Qiu, Y., Nakamichi, I., Hamada, K.-I., Ueda, T., Naka, N., Kudawara, I., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-1732 · Cited by 59
Neurofibromin as a regulator of melanocyte development and differentiation
Diwakar, G., Zhang, D., Jiang, S., & Hornyak, T. J. (2007) · Journal of Cell Science · doi:10.1242/jcs.013912 · Cited by 52
High prevalence of p53 exon 4 mutations in soft tissue sarcoma
Das, P. K., Kotilingam, D., Korchin, B., Liu, J., Yu, D., Lazar, A. J., Pollock, R. E., & Lev, D. C. (2007) · Cancer · doi:10.1002/cncr.22680 · Cited by 45
Self-citationYang, P., Hirose, T., Hasegawa, T., Seki, K., Sano, T., & Hizawa, K. (1995) · Cancer · doi:10.1002/1097-0142(19950815)76:4<618::aid-cncr2820760412>3.0.co;2-x · Cited by 41
Ren, W., Korchin, B., Zhu, Q., Wei, C., Dicker, A. P., Heymach, J. V., Lazar, A. J., Pollock, R. E., & Lev, D. C. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-4471 · Cited by 37
Self-citationClinical relevance of pRb and p53 Co-overexpression in soft tissue sarcomas
Würl, P., Meye, A., Lautenschläger, C., Schmidt, H., Bache, M., Kalthoff, H., Schönfelder, M., Rath, F.-W., & Taubert, H. W. (1999) · Cancer Letters · doi:10.1016/s0304-3835(99)00034-8 · Cited by 17
Cited by
Malignant Peripheral Nerve Sheath Tumors
Farid, M., Demicco, E. G., Garcia, R., Ahn, L., Merola, P. R., Cioffi, A., & Maki, R. G. (2014) · The Oncologist · doi:10.1634/theoncologist.2013-0328 · Cited by 354
Schaefer, I.-M., Fletcher, C. D., & Hornick, J. L. (2016) · Modern Pathology · doi:10.1038/modpathol.2015.134 · Cited by 317
Somatic mutations of SUZ12 in malignant peripheral nerve sheath tumors
Zhang, M., Wang, Y., Jones, S., Sausen, M., McMahon, K., Sharma, R., Wang, Q., Belzberg, A. J., Chaichana, K., Gallia, G. L., et al. (2014) · Nature Genetics · doi:10.1038/ng.3116 · Cited by 301
Kolberg, M., Holand, M., Agesen, T. H., Brekke, H. R., Liestol, K., Hall, K. S., Mertens, F., Picci, P., Smeland, S., & Lothe, R. A. (2013) · Neuro-Oncology · doi:10.1093/neuonc/nos287 · Cited by 270
Feasibility of using NF1-GRD and AAV for gene replacement therapy in NF1-associated tumors
Bai, R.-Y., Esposito, D., Tam, A. J., McCormick, F., Riggins, G. J., Wade Clapp, D., & Staedtke, V. (2019) · Gene Therapy · doi:10.1038/s41434-019-0080-9 · Cited by 38
Metadata
- Authors
- Zou, C., Smith, K. D., Liu, J., Lahat, G., Myers, S., Wang, W.-L., Zhang, W., McCutcheon, I. E., Slopis, J. M., Lazar, A. J., Pollock, R. E., & Lev, D.
- Venue
- Annals of Surgery
- Published
- 2009-06
- Volume
- 249
- Issue
- 6
- Pages
- 1014-1022
- ISSN
- 0003-4932 (ISSN-L)
- OpenAlex
- W2031892485
- Cited by
- 313
- References
- 37
- FWCI
- 6.56
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.